^Halpern, John H.; Suzuki, Joji; Huertas,, Pedro E.; Passie, Torsten. Price, Lawrence H.; Stolerman, Ian P., 编. Encyclopedia of Psychopharmacology A Springer Live Reference. Heidelberg, Germany: Springer-Verlag Berlin Heidelberg. 7 June 2014: 1–5 [24 April 2015]. ISBN 978-3-642-27772-6. Hallucinogen abuse and dependence are known complications resulting from the illicit use of drugs in this category, such as LSD and psilocybin. Users do not experience withdrawal symptoms, but the general criteria for substance abuse and dependence otherwise apply. Dependence is estimated in approximately 2 % of recent-onset users in the United States.
^Malenka RC, Nestler EJ, Hyman SE. Chapter 15: Reinforcement and Addictive Disorders. (编) Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd. New York: McGraw-Hill Medical. 2009: 375. ISBN 9780071481274. Several other classes of drugs are categorized as drugs of abuse but rarely produce compulsive use. These include psychedelic agents, such as lysergic acid diethylamide (LSD), which are used for their ability to produce perceptual distortions at low and moderate doses. The use of these drugs is associated with the rapid development of tolerance and the absence of positive reinforcement (Chapter 6). Partial agonist effects at 5HT2A receptors are implicated in the psychedelic actions of LSD and related hallucinogens. 3,4-Methylenedioxymethamphetamine (MDMA), commonly called ecstasy, is an amphetamine derivative. It produces a combination of psychostimulant-like and weak LSD-like effects at low doses. Unlike LSD, MDMA is reinforcing—most likely because of its interactions with dopamine systems—and accordingly is subject to compulsive abuse. The weak psychedelic effects of MDMA appear to result from its amphetamine-like actions on the serotonin reuptake transporter, by means of which it causes transporter-dependent serotonin efflux. MDMA has been proven to produce lesions of serotonin neurons in animals and humans.